RSV is a leading cause of pneumonia in the elderly.
European regulators have approved the region's first vaccine for respiratory syncytial virus (RSV), which causes thousands of hospitalisations and deaths annually.
The shot, called Arexvy, is made by British drugmaker GSK and is designed to protect people aged 60 and over.
RSV typically causes cold-like symptoms, but is a leading cause of pneumonia in toddlers and the elderly.
The complex molecular structure of the virus and safety concerns with previous vaccine attempts had stymied efforts to successfully develop a shot since the virus was first discovered in 1956.
The approval this morning by the European Commission, which follows a recent endorsement from the European Medicines Agency, comes about a month after the US health regulator the gave Arexvy the green light.
The availability of the vaccine in Europe will depend on national recommendations and reimbursement discussions, but the first launches are expected this autumn ahead of the 2023/2024 RSV season, GSK said in a statement.
The company said it does not expect a significant rollout in Europe this year

Department Of Housing Shifts Blame On To Council As Kildare Families Priced Out Of "Affordable" Housing Again
Outbreak Of Bird Flu Has Been Confirmed In Carlow Turkey Flock
Lidl To Open Country’s First Net Zero Energy Store In Maynooth This Thursday
Contract For Maynooth Eastern Ring Road Project Awarded To Company Based In Kilcullen
Policy Shift Allows Private Sector To Construct Wastewater Plants For New Housing
Parents Invited To Take Part In Major Survey On Primary Education’s Future
New "Affordable" Naas Homes Cost More Than Families Are Allowed To Borrow From Council
Minister Lawless Sought Legal Advice Over Claims Apprentice Electricians Bought Exam Papers For €50